Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular
Americas
LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.   4 May 2026
Brussels under scrutiny for IP policy as US flags risks to innovation
Americas
The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.   1 May 2026
Squire Patton Boggs promotes partner to head Europe IP&T practice
Careers
The IP expert will use his new role to support clients in cross-border challenges driven by innovation, digitalisation, market pressure and regulatory change.   1 May 2026
Americas
The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.   30 April 2026
Europe
Data from Questel indicates a radical restructuring of IP professionals’ duties, as adoption and demand rates continue to rise.   30 April 2026
Europe
The company’s rivals convinced an EPO appeals board to revoke a patent that had been used in litigation against them over Comirnaty.   30 April 2026
Careers
Patent litigator and attorney swaps the capital of Massachusetts for Los Angeles and San Francisco, bringing a broad patent practice across tech and life sciences.   30 April 2026
Americas
The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.   29 April 2026
Americas
Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug   28 April 2026
Americas
BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.   28 April 2026